NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has appointed W. Kevin Kelly, DO to serve on its Scientific and Medical Advisory Board. Dr. Kelly, an internationally respected expert in the field of urological malignancies, is Director of the solid tumor division in the Department of Medical Oncology and Associate Director of Translational Research at the Thomas Jefferson University Hospital Kimmel Cancer Center in Philadelphia.
Help employers find you! Check out all the jobs and post your resume.
